Deletion of <i>sagA</i> alone results in a decrease in nasopharyngeal infection. by Blake A. Shannon (14197601)

NEDD4 knockout decreases IFITM3 ubiquitination and protects cells from virus infection. by Nicholas M. Chesarino (781971)

Promoter reporter studies for SF-1 regulating the human <i>BDNF</i> promoter I and comparative studies of specific <i>NR5A1</i> mutations on <i>BDNF</i> promoter activity. by Jana Malikova (615672)

Subjects:

Promoter reporter studies for reported <i>NR5A1</i> mutations by Jana Malikova (615672)

Subjects:

The increased <i>in vitro</i> phagocytic activity of resKCs and recMφs against FITC-<i>E</i>. <i>coli</i> and the decreased TNF-α production by LPS-stimulated liver MNCs following... by Takuya Ishikiriyama (6735674)

Brain and liver GCase activity are significantly decreased in heterozygous <i>GBA1</i> D409V KI mice, with varying differences in glucosphingolipid lipids in brain and liver. by Nicole K. Polinski (10947787)

“…<p>(A-B) GCase, (C-D) gluocosylceramide (GlcCer), and (E-F) glucosylsphingosine (GlcSph) levels measured in whole brain homogenate and liver homogenate of C57Bl/6 wild type (WT) and <i>GBA1</i> D409V KI heterozygous (HET) mice at 5 months of age (n = 10/age). …”

GCase activity is significantly decreased in the brain and liver of the homozygous <i>GBA1</i> D409V KI mouse model at 4, 8, and 12 months of age. by Nicole K. Polinski (10947787)

“…In whole brain homogenate (A,C) and liver homogenate (B,D), GCase activity is significantly decreased in the <i>GBA1</i> D409V KI homozygous (HOM) mice as compared to C57Bl/6 wild type (WT) mice (n = 7/group). …”

PTH decreased cell apoptosis in a Flt-3L expanded population. by Flavia Q. Pirih (360515)

Significantly decreased adhesion to host cells by the Δ<i>tad123</i> mutant (A) and time-dependent recovery (B). by Tra-My Duong-Nu (7300970)

Decreased Fhl1b activity augments induction of pancreatic endocrine cells. by Jin Xu (31283)

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Subjects:

Decreased expression levels of the MYO6 protein in <i>ksv</i> mice. by Yuta Seki (4385833)

“…Expression of MYO6 is completely ablated in the hair cells of <i>Myo6</i>^-/- mice (C). Scale bar = 5 μm. D and E. Western blot analysis of homogenates prepared from the inner ears of +/+, +/<i>ksv</i> and <i>ksv/ksv</i> mice at P30 detected with anti-MYO6 (N-ter, D) and MYO6 (C-ter, E) antibodies (<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0183477#pone.0183477.s007" target="_blank">S2 Table</a>). …”

Three Ca_V3.3 variants left-shift the window current, while the A398V completely abolishes the window current. by Yousra El Ghaleb (22075892)

Subjects:

Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

Subjects:

Study Flow Diagram. by Elizabeth S. Munroe (21568166)

Subjects:

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects: